Serum IL-1β, sIL-2R, IL-6, IL-8 and TNF-α in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment
Open Access
- 1 January 2001
- journal article
- research article
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 10 (3), 109-115
- https://doi.org/10.1080/09629350123895
Abstract
Activation of the inflammatory response system and varied levels of cytokines in acute schizophrenia have been suggested by recent studies. Psychopharmacologic agents can differentially effect cytokine production, which suggests that therapeutic function of neuroleptics may involve immunomodulation.The present study was carried out to examine: (i) serum concentrations of interleukin (IL)-1β , soluble interleukin-2 receptor (sIL-2R), IL-6, IL-8 and tumour necrosis factor (TNF)- α in schizophrenic patients; (ii) their relation with psychopathological assessment; and (iii) the relation of the initial cytokine levels with responsiveness to risperidone therapy.Thirty-four drug-free schizophrenic patients with acute exacerbation and 23 age- and gender-matched healthy controls were recruited for this study. Psychopathological assessments at admission and throughout risperidone treatment for 60 days were recorded. Serum cytokine concentrations were determined with chemilumunescence assays.According to our results, serum IL-1β , sIL-2R, IL-6, IL-8 and TNF-α concentrations adjusted for age, gender, body mass index and smoking were no different in patients with schizophrenia and controls and among subtypes of schizophrenia. However, the initial TNF-α concentrations had a significant effect on Brief Psychiatric Rating Scale and Scale Assessment of Positive Symptoms scores. The initial cytokine concentrations of the patients responsive to risperidone were not significantly different from those of non-responsive patients.The present study demonstrates that plasma levels of IL-1β , sIL-2R, IL-6, IL-8 and TNF-α adjusted for confounding factors are not altered in drug-free schizophrenic patients at acute exacerbation. We suggest that, if cytokine production is altered in schizophrenia, these alterations may not be detectable in systemic circulation. According to our results, the therapeutic effect of risperidone is not related to basal levels of the aforementioned cytokines. However, serum TNF-α may contribute to symptomatology in schizophrenia.Keywords
This publication has 27 references indexed in Scilit:
- Cytokines and the Brain: Implications for Clinical PsychiatryAmerican Journal of Psychiatry, 2000
- Elevated interleukin-6 in schizophreniaPsychiatry Research, 1999
- A differential role for interleukin-6 and tumor necrosis factor-α in schizophrenia?Schizophrenia Research, 1997
- Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugsSchizophrenia Research, 1996
- Serum cytokine concentrations in patients with schizophreniaSchizophrenia Research, 1996
- Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizersJournal of Psychiatric Research, 1995
- Changes in Interleukin-1β and Soluble Interleukin-2 Receptor Levels in CSF and Serum of Schizophrenic PatientsJournal of Basic and Clinical Physiology and Pharmacology, 1995
- Serum interleukin-6 in schizophrenic patientsLife Sciences, 1991
- Decreased interleukin-2 production in schizophrenic patientsBiological Psychiatry, 1989
- Increased Serum Interleukin 2 Receptor Concentration in Schizophrenic and Brain-Damaged SubjectsArchives of General Psychiatry, 1989